FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2933598993> ?p ?o ?g. }

• W2933598993 endingPage "219.e1" @default.
• W2933598993 startingPage "212" @default.
• W2933598993 abstract "Objectives To assess clinical outcomes in children treated with unfractionated heparin and monitored using an anti-factor Xa (Anti-FXa)-based nomogram. We also sought to assess the correlation between activated partial thromboplastin time (APTT) and Anti-FXa. Study design This was a single-center, observational cohort study conducted over a 20-month period that included all pediatric patients (<21 years) who received therapeutic unfractionated heparin and were monitored using an anti–FXa-based nomogram. Results In total, 95 patients met prespecified inclusion criteria, and 1098 pairs of APTT and Anti-FXa measurements were performed. The median unfractionated heparin dose required to reach therapeutic Anti-FXa goal was significantly greater in infants compared with older children (P <.0001). The median time to achieve therapeutic Anti-FXa was 10 hours (range 2-96 hours) and was significantly shorter in patients who received a bolus compared with those who did not (P = .03). Five (5.3%) major bleeding events were noted. Age, peak Anti-FXa, peak APTT, lowest platelet count, and fibrinogen were not predictive of major and clinically relevant nonmajor bleeds. Moderate correlation between the APTT and Anti-FXa (r = 0.75; 95% CI 0.72-0.77) assays was appreciated. Conclusions Using an anti–FXa-based nomogram to monitor unfractionated heparin in children is feasible. Although moderate correlation was observed between the APTT and Anti-FXa assays, the APTT frequently overestimated heparin activity. Safety and efficacy of an Anti-FXa nomogram needs further validation. To assess clinical outcomes in children treated with unfractionated heparin and monitored using an anti-factor Xa (Anti-FXa)-based nomogram. We also sought to assess the correlation between activated partial thromboplastin time (APTT) and Anti-FXa. This was a single-center, observational cohort study conducted over a 20-month period that included all pediatric patients (<21 years) who received therapeutic unfractionated heparin and were monitored using an anti–FXa-based nomogram. In total, 95 patients met prespecified inclusion criteria, and 1098 pairs of APTT and Anti-FXa measurements were performed. The median unfractionated heparin dose required to reach therapeutic Anti-FXa goal was significantly greater in infants compared with older children (P <.0001). The median time to achieve therapeutic Anti-FXa was 10 hours (range 2-96 hours) and was significantly shorter in patients who received a bolus compared with those who did not (P = .03). Five (5.3%) major bleeding events were noted. Age, peak Anti-FXa, peak APTT, lowest platelet count, and fibrinogen were not predictive of major and clinically relevant nonmajor bleeds. Moderate correlation between the APTT and Anti-FXa (r = 0.75; 95% CI 0.72-0.77) assays was appreciated. Using an anti–FXa-based nomogram to monitor unfractionated heparin in children is feasible. Although moderate correlation was observed between the APTT and Anti-FXa assays, the APTT frequently overestimated heparin activity. Safety and efficacy of an Anti-FXa nomogram needs further validation." @default.
• W2933598993 created "2019-04-11" @default.
• W2933598993 creator A5014146308 @default.
• W2933598993 creator A5027676114 @default.
• W2933598993 creator A5032813653 @default.
• W2933598993 creator A5037978171 @default.
• W2933598993 creator A5050829820 @default.
• W2933598993 creator A5051210012 @default.
• W2933598993 creator A5053040794 @default.
• W2933598993 date "2019-06-01" @default.
• W2933598993 modified "2023-10-14" @default.
• W2933598993 title "Anti-Factor Xa–Based Monitoring of Unfractionated Heparin: Clinical Outcomes in a Pediatric Cohort" @default.
• W2933598993 cites W1523598805 @default.
• W2933598993 cites W1564175447 @default.
• W2933598993 cites W1823591369 @default.
• W2933598993 cites W1964477223 @default.
• W2933598993 cites W1978963939 @default.
• W2933598993 cites W1981028815 @default.
• W2933598993 cites W1993357981 @default.
• W2933598993 cites W2001610776 @default.
• W2933598993 cites W2003915795 @default.
• W2933598993 cites W2025513998 @default.
• W2933598993 cites W2039989814 @default.
• W2933598993 cites W2041829143 @default.
• W2933598993 cites W2054730686 @default.
• W2933598993 cites W2056549587 @default.
• W2933598993 cites W2060932201 @default.
• W2933598993 cites W2071719603 @default.
• W2933598993 cites W2072673292 @default.
• W2933598993 cites W2075586423 @default.
• W2933598993 cites W2080318130 @default.
• W2933598993 cites W2085029573 @default.
• W2933598993 cites W2106459062 @default.
• W2933598993 cites W2125071170 @default.
• W2933598993 cites W2131236362 @default.
• W2933598993 cites W2137920545 @default.
• W2933598993 cites W2138679315 @default.
• W2933598993 cites W2139716972 @default.
• W2933598993 cites W2153738815 @default.
• W2933598993 cites W2169291800 @default.
• W2933598993 cites W2169866483 @default.
• W2933598993 cites W2261003870 @default.
• W2933598993 cites W2288932954 @default.
• W2933598993 cites W2329761741 @default.
• W2933598993 cites W2396246764 @default.
• W2933598993 cites W2463444425 @default.
• W2933598993 cites W2750945684 @default.
• W2933598993 cites W2795377270 @default.
• W2933598993 cites W4299916133 @default.
• W2933598993 cites W4323282386 @default.
• W2933598993 cites W4324114151 @default.
• W2933598993 doi "https://doi.org/10.1016/j.jpeds.2019.02.015" @default.
• W2933598993 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30961988" @default.
• W2933598993 hasPublicationYear "2019" @default.
• W2933598993 type Work @default.
• W2933598993 sameAs 2933598993 @default.
• W2933598993 citedByCount "10" @default.
• W2933598993 countsByYear W29335989932019 @default.
• W2933598993 countsByYear W29335989932020 @default.
• W2933598993 countsByYear W29335989932021 @default.
• W2933598993 countsByYear W29335989932022 @default.
• W2933598993 countsByYear W29335989932023 @default.
• W2933598993 crossrefType "journal-article" @default.
• W2933598993 hasAuthorship W2933598993A5014146308 @default.
• W2933598993 hasAuthorship W2933598993A5027676114 @default.
• W2933598993 hasAuthorship W2933598993A5032813653 @default.
• W2933598993 hasAuthorship W2933598993A5037978171 @default.
• W2933598993 hasAuthorship W2933598993A5050829820 @default.
• W2933598993 hasAuthorship W2933598993A5051210012 @default.
• W2933598993 hasAuthorship W2933598993A5053040794 @default.
• W2933598993 hasConcept C126322002 @default.
• W2933598993 hasConcept C141071460 @default.
• W2933598993 hasConcept C2777557582 @default.
• W2933598993 hasConcept C2778261982 @default.
• W2933598993 hasConcept C2779036427 @default.
• W2933598993 hasConcept C34626388 @default.
• W2933598993 hasConcept C42219234 @default.
• W2933598993 hasConcept C71924100 @default.
• W2933598993 hasConcept C72563966 @default.
• W2933598993 hasConcept C89560881 @default.
• W2933598993 hasConceptScore W2933598993C126322002 @default.
• W2933598993 hasConceptScore W2933598993C141071460 @default.
• W2933598993 hasConceptScore W2933598993C2777557582 @default.
• W2933598993 hasConceptScore W2933598993C2778261982 @default.
• W2933598993 hasConceptScore W2933598993C2779036427 @default.
• W2933598993 hasConceptScore W2933598993C34626388 @default.
• W2933598993 hasConceptScore W2933598993C42219234 @default.
• W2933598993 hasConceptScore W2933598993C71924100 @default.
• W2933598993 hasConceptScore W2933598993C72563966 @default.
• W2933598993 hasConceptScore W2933598993C89560881 @default.
• W2933598993 hasLocation W29335989931 @default.
• W2933598993 hasLocation W29335989932 @default.
• W2933598993 hasOpenAccess W2933598993 @default.
• W2933598993 hasPrimaryLocation W29335989931 @default.
• W2933598993 hasRelatedWork W1581814344 @default.
• W2933598993 hasRelatedWork W2003003493 @default.
• W2933598993 hasRelatedWork W2031219338 @default.
• W2933598993 hasRelatedWork W2059694493 @default.

• next